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A toolset of functionalized porphyrins with
diﬀerent linker strategies for application in
bioconjugation†
M. H. Staegemann,a,b S. Gräfe,b R. Haag*a and A. Wiehe*a,b
The reaction of amines with pentaﬂuorophenyl-substituted A3B-porphyrins has been used to obtain
diﬀerent useful reactive groups for further functionalization and/or conjugation of these porphyrins to
other substrates or materials. Porphyrins with alkenyl, alkynyl, amino, azido, epoxide, hydroxyl, and male-
imido groups have thus been synthesized. For the ﬁrst time such functionalized porphyrins have been
conjugated to hyperbranched polyglycerol (hPG) as a biocompatible carrier system for photodynamic
therapy (PDT) using the copper(I)-catalyzed 1,3-dipolar cycloaddition (CuAAC). The photocytotoxicity of
selected porphyrins as well as of the porphyrin-hPG-conjugates has been assessed in cellular assays with
human epidermoid carcinoma A-253 and squamous carcinoma CAL-27 cells. For several biomedical
applications a release of the active drug and/or ﬂuorescent dye is desired. Therefore, additionally, the syn-
thesis of A3B-porphyrins with cleavable linker moieties is presented, namely disulﬁde, cleavable in a
reductive environment, and acetal linkers whose cleavage is pH triggered.
Introduction
Cyclic tetrapyrrolic systems are essential in many biological
processes and are also of interest for diverse applications
such as photodynamic therapy (PDT),1–6 light-harvesting,7,8 or
catalysis.9–11 PDT is a treatment modality for malignant
tissues, which is today routinely applied for the treatment of
certain forms of cancer.1–6 In PDT, a dye – the so-called photo-
sensitizer – and light are combined to provoke a toxic eﬀect in
the tumor cells. Diﬀerent photosensitizers based on tetrapyrro-
lic structures are described in literature: e.g. chlorins and
bacteriochlorins,2,12–17 porphyrins,2,5,6 phthalocyanines,18,19
and corroles.20,21 When choosing porphyrins as tetrapyrrolic
systems, these may also be transformed into the corresponding
chlorins or bacteriochlorins which are even more potent
photosensitizers.2,12–17 If the connection to carriers or other
substrates is intended porphyrins of the A3B-type (with ‘B’
being the substituent suitable for coupling) are preferable to
assure a specific linkage without undesired crosslinking. One
way to obtain such specifically functionalized tetrapyrroles is
the nucleophilic aromatic substitution reaction of a fluorine
atom in pentafluorophenyl-substituted tetrapyrrolic systems.
Diﬀerent nucleophiles have been used like amines,5,22–25
alcohols,5,26–28 carborane,29 phosphanes,30 phosphite,31 and
thiols.14,26,32 Thereby, the reaction with amines or thiols does
not require any addition of catalysts or other reagents (e.g.
bases),5,22–25 which simplifies reaction conduct and workup.
In this work the functionalization of A3B-type pentafluoro-
phenyl containing porphyrins with amines is described,
specifically intended for conjugation of these porphyrins to
other substrates, carrier systems or material surfaces. An easy
and convenient way is shown to introduce the following func-
tionalities: alkenyl, alkynyl, amino, azido, epoxide, hydroxyl,
and maleimido. The alkynyl-substituted porphyrin was chosen
for further linkage – via the copper(I)-catalyzed 1,3-dipolar cyclo-
addition (CuAAC) – to a second porphyrin, to glyco-substituents,
and especially to hyperbranched polyglycerol (hPG), as a promi-
nent example for a biocompatible carrier system,33–37 exemplify-
ing the applicability of this method. One of the important
issues with respect to carrier systems for medically active sub-
stances is the site-specific release of the active substance from
the carrier.38–41 To provide such cleavable linkages porphyrins
carrying disulfide or acetal linkers are also presented.
Synthesis
The focus of this work is the synthesis of substituted por-
phyrin systems to obtain a toolkit for cleavable and non-cleav-
able linkers to diﬀerent substrates e.g. carrier systems, surfaces
or the formation of multimeric systems. In literature diﬀerent
tetrapyrroles have been described and used for further
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linkage.42–44 Only little has been reported in this respect on
the synthesis of porphyrins with cleavable linkers that should
allow the release from a substrate or carrier system, which is of
interest for many biological applications.45–47
In the literature a number of nucleophilic aromatic substi-
tutions with amines on pentafluorophenyl-substituted por-
phyrins have been described involving however mainly the
tetra-substituted derivatives.5,22–26,30 For the purpose of
specific linkage mono-pentafluorophenyl-substituted porphyr-
ins (A3B systems) are preferable therefore we expanded the sub-
stitution reaction onto these porphyrin systems (Scheme 1).
The reaction was performed with porphyrins carrying
3-acetoxyphenyl 1a,27,48 3-benzyloxyphenyl 1b 27 or 3-hydroxy-
phenyl 1c 27,48 groups as R1 (substituent A). The structure of
the A3B porphyrins with (protected) 3-hydroxyphenyl groups is
inspired by the structure of the photosensitizer Temoporfin
(5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin, mTHPC) which
is one of the few photosensitizers currently approved for clini-
cal use.49 The polar hydroxyphenyl groups thereby increase the
solubility of the hydrophobic macrocycle in the biological
environment and enhance membrane aﬃnity.49
The diﬀerent amines and detailed conditions are given in
Table 1. The reaction was performed in DMSO at 83 °C (b.p. of
propargylamine) or 100 °C. The reaction with the diamine
cystamine under these conditions led to degradation of the
disulfide linker resulting in low yield (results not shown).
Therefore the reaction was tried under microwave conditions
(Table 1, entry 1). Using the microwave the reaction time gets
shorter at the same time the yield is improved, showing that
with this method it is possible to introduce labile functional-
ities, like the disulfide-containing cystamine. The diﬀerent
polarities of R1 did not interfere with the reactivity of the
amines, therefore unpolar substituents like 3-benzyloxyphenyl
can be used as well as the polar 3-hydroxyphenyl group.
However, the more polar 3-hydroxyphenyl group is of higher
interest for biological applications due to its close analogy to
the photosensitizer Temoporfin.
Employing the 3-acetoxyphenyl residues it is possible to do
a two-step one-pot reaction.27,48 The amine acts as a nucleo-
phile for the nucleophilic aromatic substitution and simul-
taneously removes the acetoxy protection groups resulting in
the functionalized A3B-porphyrin with three polar hydroxy-
phenyl groups. This is shown with the example of the acetoxy-
protected porphyrin 1a which on reaction with excess
propargylamine directly aﬀorded the deprotected and
propargylamino-substituted compound 2f. This simplifies the
synthesis of substituted A3B porphyrins and makes it possible
to get to the final product in only two steps starting from
pyrrole and aldehydes. The unsubstituted and the two
propargylamino-substituted porphyrins 1c and 2f,g (Scheme 2)
were further converted to their corresponding zinc-complexes
1d and 2h,i obtained between 73% and quant. yield.
Mono-functionalized porphyrins like 2a–g should in prin-
ciple also be accessible by the mono-functionalization of the
tetrakispentafluorophenyl-substituted porphyrin 3 (Scheme 3).
To test this 3 was reacted with propargylamine. Under opti-
mized reaction conditions (DMSO/THF mixture, 1.5 h reaction
Scheme 1 Regioselective nucleophilic aromatic substitution of A3B
porphyrins 1a–c with diﬀerent amines. R2-NH2 is deﬁned as in Table 1.
Reagents and conditions: DMSO, 0.5–7 h, 83–100 °C (detailed con-
ditions and yields are given in Table 1).
Table 1 Reactions of the A3B porphyrins 1a–c with amines in DMSO
Entry Starting material Amine R1 Conditionsa Product Yieldb [%]
1 1c Cystamine H 30 min, 100 °C microwave (300W) 2a 87
2 1c 1,4-Diaminobutane H 1 h, 100 °C 2b 69
4 1c 1,5-Diaminopentane H 1 h, 100 °C 2c 54
5 1c 1,6-Diaminohexane H 1 h, 100 °C 2d 79
3 1c 1-(N-Boc-),5-diaminopentane H 4 h, 100 °C 2e 69
6 1a Propargylamine Ac 3 h, 83 °C 2f c 94
7 1b Propargylamine Bn 7 h, 100 °C 2g 78
a All the reactions were carried under argon in a sealed reaction vessel. b Yield of isolated product after purification. c In product R1 = H; the basic
propargylamine simultaneously removes the acetyl protection groups.
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time) the mono-propargylamino-substituted porphyrin 4 could
be obtained in 22% yield, in addition, the disubstituted com-
pound carrying two propargylamino-substituents was also iso-
lated (18%, not shown). The A3B porphyrin 4 carries only one
propargylamino-substituent it lacks, however, the polar
hydroxyphenyl-substitution of 2a–g which significantly con-
tributes to the solubility of the hydrophobic macrocycle in the
biological environment.49 To overcome this, a subsequent
modification of the three remaining pentafluoropheny-substi-
tuents e.g. by nucleophilic substitution would be necessary.
The free amino group of the porphyrins 2a–d is a useful
and reactive functionality for further modifications. It is poss-
ible to use it directly for the linkage to carriers or substrates.
Use of amide coupling, e.g. allows the introduction of other
linkage functionalities (Scheme 4). On the one hand it is possi-
ble to directly use a carboxylic acid, here propynoic acid, with
DCC and 1-hydroxybenzotriazole hydrate (HOBt hydrate). This
method is commonly used in peptide synthesis and prevents
the formation of N-acylurea.50 The porphyrins 2a and 2b, propy-
noic acid, HOBt hydrate, and dicyclohexylcarbodiimide (DCC)
in THF were stirred for 130 min at RT. The crude products were
purified by column chromatography to aﬀord the porphyrins 5a
and 5b with a yield of 33 and 77%, respectively. Products 5a,b
and the zinc complex 5c carry the alkyne functionality which
allows the CuAAC in further reactions; in addition 5b and 5c
incorporate a cleavable disulfide linker as well.
On the other hand we used an active ester, which allows
reactions with compounds containing amino-sensitive groups.
One example is the maleimido functionality, which can
undergo a reaction with the free amine of the porphyrin.
Scheme 4 shows the reaction of 3-(maleimido)propionic acid
N-hydroxysuccinimide ester with the porphyrins 2a, 2c and 2d.
The porphyrins 2a,c,d and 3-(maleimido)propionic acid
N-hydroxysuccinimide ester were stirred in DMF for 1 h at RT.
The crude products were purified by column chromatography
to aﬀord the porphyrins 6a–c in high yields between 65 and
81%. The introduced maleimido functionality is useful for
metal free conjugations of these porphyrins to substrates,
additionally avoiding the complexation of the metal by the por-
phyrin which is a common problem in reactions of porphyrins
involving transition metal catalysts.
For aﬀording the release of the porphyrin it is necessary to
introduce labile linker bonds. It is important that these bonds
are predominantly cleaved when the active agent has reached its
target. Above, the synthesis of thiol-disulfide linker-containing
porphyrins 5b and 6a has been described (Scheme 4). This linker
moiety can be used for drug delivery and is relying on the diﬀer-
ence of the redox potential between the cytosol and the blood
stream. In the blood stream the global potential is mildly oxi-
dative.47,51 The intracellular environment is reductive on the other
hand because of the fact that the concentration of glutathione
(GSH) is 103 fold higher compared to its counterpart, GSSG.52,53
In literature it is described that disulfide bonds are reduced in
the cytosol, making the release of drugs possible.47,51,54,55
Another way is the pH-triggered cleavage via acetal linkers.
By the time a conjugate or compound is taken up by the cell
Scheme 2 Zinc insertion into the A3B porphyrins 1c, 2f and 2g. Reagents
and conditions: Zn(OAc)2, NaOAc, MeOH or MeOH/DCM, 1–2 h, RT.
Scheme 3 Synthesis of the mono-functionalized porphyrin 4.
Reagents and conditions: propargylamine, DMSO/THF (1/1), 1.5 h,
100 °C.
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Scheme 4 Substitution of the A3B porphyrins 2a–d with free amine end groups via amide coupling with propynoic acid or 3-(maleimido)propionic
acid N-hydroxysuccinimide ester. Reagents and conditions: (i) propynoic acid, HOBt hydrate, DCC, THF, 130 min, RT; (ii) 3-(maleimido)propionic acid
N-hydroxysuccinimide, DMF, 1 h., RT; (iii) Zn(OAc)2, NaOAc, MeOH, 30 min, RT (see Experimental section for further details).
Scheme 5 Acetal formation with the A3B porphyrin 7. Reagents and conditions: (i) 4-hydroxybenzaldehyde or 4-(oxiran-2-ylmethoxy)benz-
aldehyde, trimethyl orthoformate, indium(III) triﬂuoromethane sulfonate, neat, 3–27 h, RT. (ii) 1-(Allyloxy)-4-(dimethoxymethyl)benzene, trimethyl
orthoformate, indium(III) triﬂuoromethane sulfonate, nitromethane/THF (5/1), 72 h, RT (see Experimental section for details).
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the pH drops from 7.4 to 5–6 in endosomes and even down to
4.5 in lysosomes.47,56 Yet, the acetal-linkage is stable in the
blood at pH 7.4.47 Once taken up by the cell via endocytosis
the linker can then be cleaved in the endosomes or lysosomes.
To evaluate the possibility to introduce an acetal-linker into
the porphyrin periphery the glycerol-substituted A3B porphyrin
7 57,58 was reacted with the corresponding aldehyde or
dimethoxy-acetal to obtain the acetal linker-containing
porphyrins 8a–c and 9 with yields between 27 and 75%
(Scheme 5). Employing this method functional linker groups
like epoxy, allyl, and phenolic hydroxyl were introduced. These
groups make a further functionalization or linkage to a sub-
strate possible.
The aim was to develop a toolset for linking porphyrins to
various molecular substrates. A versatile, fast and easy reaction
for connecting diﬀerent molecules is the CuAAC. It is com-
monly applied in organic,59 polymer,60 materials,61 and medic-
inal chemistry.62,63 Therefore, in the next step the suitability of
the alkynyl-substituted porphyrins 2h,i in the CuAAC-coupling
reaction was assessed (Scheme 6).
Scheme 6 Modiﬁcation of the A3B porphyrins 2h,i via CuAAC. Reagents and conditions for all reactions: CuSO4·5H2O, L-ascorbic acid sodium salt,
DMSO, 0.5–75 h, RT – 60 °C (see Experimental section for details).
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The reaction of 2h with 3-azidopropanol conveys a change
in the functionality from an alkyne to a hydroxyl group (in
10a) with a yield of 89%. Also the increased hydrophilicity may
be favorable for a possible biological application. Glycosylated
porphyrins are of great interest for the use in PDT and other
fields, as they make it more specific and eﬀective.64,65
Therefore in a test reaction alpha-D-glucose was connected to
porphyrin 2i. Cancer cells show an increased uptake of
glucose, which provides metabolic energy and maintains their
proliferation.66,67 In various cancer cells glucose transporter
proteins are over-expressed.67,68 We used 2-azido-beta-D-
glucose tetraacetate which was formed in situ from aceto-
bromo-alpha-D-glucose tetraacetate and sodium azide and
reacted it with 2i to obtain the glucosylated porphyrin 11 with
a yield of 17%. A large number of such CuAAC-mediated glyco-
sylations are already described in the literature.64,65,69,70
To obtain the symmetric dimeric porphyrin 10c and the
azido-porphyrin 10b (with a functionality swap from alkynyl to
azido) 1,3-diazidopropane was reacted with the alkynyl-substi-
tuted porphyrin 2h. It is noteworthy that even with a high
excess of 1,3-diazidopropane partial dimer formation is
observed. This indicates that the reactivity of the azido-
porphyrin 10b is higher compared to the 1,3-diazidopropane
itself. Mannose units are known to interact with mannose
receptors on the bacterial membranes which makes
porphyrin–mannose conjugates possible candidates for anti-
bacterial PDT.71–73 Therefore the azido-porphyrin 10b with the
inversed end group was then further functionalized with pro-
pargyl-α-D-mannopyranoside to directly obtain the corres-
ponding deprotected glycosylated porphyrin 10d.
Finally, the polar alkynyl-substituted porphyrin 2h was
reacted with hPG19.5- or hPG116-azides 12a–d under CuAAC
conditions (Scheme 7 and Table 2). By this the porphyrin-
hPG19.5-conjugates 13a–c were obtained which are the first
examples of conjugates combining porphyrins and the hPG
carrier system. hPG is an ideal drug carrier for medical appli-
cations. The synthesis of the chemically stable hPG can easily
be upscaled to the kilogram scale and the conjugate still pos-
sesses hydroxyl groups for further functionalization,33,34,37,74,75
allowing e.g. the attachment of targeting moieties.34,74 hPG is
highly water soluble and tests in vitro and in vivo showed a
good biocompatibility.35,36,75–77 Moreover, it shows high photo-
stability which is advantageous with respect to its use in a
photomedical application.
hPG systems with diﬀerent degrees of azide loading were
used78 and reacted with diﬀerent amounts of the porphyrin 2h
to obtain a range of porphyrin loadings. In Table 2 the por-
phyrin loading is given as the approximate number of por-
phyrin groups. The degree of loading was determined by NMR
spectroscopy by correlating the aromatic with the polyglycerol
backbone protons as described in the literature.79–82
The conjugates 13a,c were further functionalized with
methoxypoly(ethylene glycol) (mPEG)-propargyl ether leading
to the porphyrin-mPEG-hPG19.5-conjugates 14a,b. It is known
that PEGylation can be beneficial for in vivo applications as it
increases the water solubility and renal clearance.83,84 Another
Scheme 7 Functionalization of hPG with the A3B porphyrin 2h via
CuAAC. Porphyrin-, azide- and mPEG-loading of the conjugates 12a–d,
13a–c and 14a,b are given in Table 2. Reagents and conditions: (i)
CuSO4·5H2O, L-ascorbic acid sodium salt, DMSO, 5 min – 75 h, RT –
40 °C; (ii) CuSO4·5H2O, L-ascorbic acid sodium salt, H2O or acetone/
H2O = 11/4, v/v, 24–48 h, RT (see Experimental section for details).
Table 2 Core size and loading (porphyrin, azide and mPEG) of the hPG










1 12a 19.5 — ∼34 —
2 12b 116 — ∼78 —
4 12c 19.5 — ∼5 —
5 12d 19.5 — ∼53 —
6 13a 19.5 ∼8 ∼26 —
7 13b 116 ∼63 ∼16 —
8 13c 19.5 ∼1 ∼4 —
9 14a 19.5 ∼1 ∼1 ∼3
10 14b 19.5 ∼8 ∼18 ∼8
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advantage is the possible use as a carrier with so-called
‘stealth’ properties, which hides the nanoparticles from the
mononuclear phagocytotic system.85 The porphyrin-hPG-
conjugates 13a–c and the conjugates with additional PEGs
14a,b are examples for active substance-loaded nanocarrier
systems, which may benefit from two eﬀects: the enhanced
permeability and retention (EPR)-eﬀect86–89 and the photo-
sensitizer-properties of the porphyrin. This makes them
promising candidates for PDT.
In summary, using the nucleophilic substitution on a meso-
mono-pentafluoro-substituted porphyrin carrying as additional
meso-substituents three (protected) hydroxyphenyl groups a set
of functionalized A3B-porphyrins suitable for the connection
to carrier systems and other substrates has been prepared. The
specific advantage of the present approach is that – starting
from pyrrole and aldehyde – in only two steps (porphyrin con-
densation, nucleophilic functionalization and simultaneous
deprotection) polar 3-hydroxyphenyl-substituted porphyrins
with a single specific coupling site are obtained. The yields for
the basic porphyrin condensation are typical for those involv-
ing the statistical condensation of two aldehydes and pyrrole
(∼10%), the yields for the nucleophilic functionalization are
good to very good (54–94%). As an alternative approach the
selective mono-functionalization of a tetrakis(pentafluoro-
phenyl)-substituted porphyrin has also been tested. The syn-
thesized compounds benefit from their structural similarity
with the clinically applied photosensitizer Temoporfin. For an
application in the CuAAC zinc insertion in the alkynyl-substi-
tuted porphyrin was necessary as a third step. These polar por-
phyrins were coupled to hPG, as a prominent example of a
biocompatible drug carrier system. With set of compounds at
hand, we set out to investigate the photocytotoxicity of selected
functionalized porphyrins and of the hPG-photosensitzer con-
jugates in two cancer cell lines to prove the feasibility of this
approach in PDT.
Photocytotoxicity in cellular assays
The photocytotoxicity of the free porphyrin dyes 2h, 5c, 10a,
10b, and 10d was evaluated in cellular assays with human epi-
dermoid carcinoma A-253 and squamous carcinoma CAL-27
cells (Fig. 1 and 2) (see Experimental section for details). The
assays were carried out after incubation for 24 h with the
photosensitizer in medium containing 10% fetal calf serum
(FCS). After the 24 h incubation the medium was exchanged to
ensure that only photosensitizer that has been taken up by the
cells contributes to the observed eﬀect. Both, the dark and the
phototoxicity were determined at two diﬀerent sensitizer con-
centrations (2 and 10 μmol). A white light source at a dose rate
of app. 50 J cm−2 was used for irradiation. Additionally, zinc
porphyrin 15, [5,10,15,20-tetrakis(3-hydroxyphenyl)porphyri-
nato]-zinc(II),90 was tested for comparison. Porphyrins 2h, 5c,
10a, and 10b show phototoxicity at 10 µM concentrations and in
both cell lines, and exhibited a somewhat higher activity than
the control sensitizer 15. At the concentration of 2 µM the por-
phyrins 2h, 10a, and 10b show increased phototoxicity against
the cell line CAL-27. For A-253 cells the highest phototoxicity
at the concentration of 2 µM is observed with porphyrin 10a.
Porphyrins with terminal hydroxyl groups are described in lit-
erature to exhibit a higher phototoxicity.5 In this case for por-
phyrin 10a a much better eﬃcacy compared to the control
porphyrin 15 was observed. The zinc-porphyrin 10d with the
mannose functionality displayed a lower toxicity and was only
active at a concentration of 10 μmol. Hence, in this case
neither the mannose substitution nor the concomitant
increase in polarity via the additional OH groups did increase
Fig. 1 Photocytotoxicity of the porphyrins 2h, 5c, and 10a in cellular
assays with human epidermoid carcinoma A-253 and squamous carci-
noma CAL-27 cells, irradiated with a white light source (see
Experimental section for details). DT: dark toxicity.
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the phototoxicity of the sensitizer. None of the tested sensi-
tizers showed dark toxicity in the CAL-27 cell line. Compounds
2h, 10a, and the control zinc porphyrin 15 showed only minor
dark toxicity at the highest concentration of 10 µmol in the
A253 cell line.
Furthermore, the photocytotoxicity of the porphyrin-hPG-
conjugates without and with PEG 13a,b and 14a,b, respectively,
were evaluated in the A-253 and the CAL-27 cell line (Fig. 3
and 4). As a control hPG19.5-azide 12d with approx. 53 azido
groups was tested to evaluate the toxicity of the carrier
polymer.
All of the conjugates except of the hPG19.5-azide control 12d
showed phototoxicity at 10 µM concentrations in both cell
lines. The highest phototoxicity was observed for the conjugate
with approx. 8 porphyrin and 8 PEG groups 14b which exhibi-
ted a higher activity than the unfunctionalized zinc porphyrin
15. Presumably, the higher PEGylation of the carrier increases
Fig. 2 Photocytotoxicity of the porphyrins 10b, 10d, and control 15,
[5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrinato]-zinc(II), in cellular
assays with human epidermoid carcinoma A-253 and squamous carci-
noma CAL-27 cells, irradiated with a white light source (see
Experimental section for details). DT: dark toxicity.
Fig. 3 Photocytotoxicity of the porphyrin-hPG-conjugates 13a, 13b,
and 14a in cellular assays with human epidermoid carcinoma A-253 and
squamous carcinoma CAL-27 cells, irradiated with a white light source
(see Experimental section for details). DT: dark toxicity.
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the solubility of the conjugate leading to a better availability of
the photosensitizer.84 At the concentration of 2 µM the conju-
gates 13a and 14a,b show increased phototoxicity against the
cell line CAL-27. For all conjugates in the two cell lines no or
only minor dark toxicity was observed. The hPG19.5-azide 12d
as a control does not show any significant toxicity with or
without irradiation. The results show that the linkages do not
impair the phototoxicity in the investigated cell lines com-
pared to the basic porphyrin.
Conclusions
The reaction of mono-meso-pentafluorophenyl-substituted A3B-
type porphyrins with various amines has been employed in the
context of functionalizing porphyrins for the conjugation to
carrier systems for PDT. The nucleophilic substitution with
amines aﬀorded a set of diﬀerent A3B porphyrins with func-
tional linkers i.e. alkenyl, alkynyl, amino, azido, epoxide,
hydroxyl, and maleimido groups. Amide coupling of the por-
phyrins containing an amine functionality has been exempli-
fied with propynoic acid and 3-(maleimido)propionic acid
N-hydroxysuccinimide ester. The maleimido groups allow the
linkage to certain other substrates (e.g. thiols) without the use
of any catalyst. The versatility of the alkynyl-substituted A3B
porphyrins for the CuAAC (Click reaction) has been demon-
strated by the linkage to another porphyrin (dimer formation)
and to sugar moieties. Finally for the first time porphyrins
were conjugated to hPG as a biocompatible carrier system.
Additionally, the synthesis of porphyrins with a cleavable
linker and functional groups for further connections was
established. Thus, a porphyrin with a reductively cleavable
disulfide-bridge was obtained as well as porphyrins with a
pH sensitive acetal linker. Overall, a toolkit for the function-
alization of porphyrins with linkers for (bio-)conjugation is
introduced. It could be shown that these linkages did not
impair the phototoxicity in the investigated cell lines com-
pared to the basic porphyrin which is an important prerequi-
site for their application in (bio-)conjugation. Cellular assays
of selected zinc-porphyrins and porphyrin-hPG-conjugates




2,3,4,5,6-Pentafluorobenzaldehyde was purchased from
Fluorochem. Acetobromo-alpha-D-glucose stabilized with 1%
CaCO3 (98%); 3-acetoxybenzaldehyde (97%); indium(III) tri-
fluoromethane sulfonate (99%); and pyrrole (98%) were pur-
chased from ABCR. L-Ascorbic acid sodium salt (99%); 1,5-
diaminopentane (98%); 2,3-dichloro-5,6-dicyano-1,4-benzo-
quinone (DDQ) (98%); dimethyl sulfoxide (DMSO) (≥99.7%)
extra dry over molecular sieves; dimethylformamide (DMF)
(99.8%) extra dry over molecular sieves; nitromethane (≥99%);
tetrahydrofuran (THF), (99.5%), extra dry over molecular sieve,
stabilized, AcroSeal®; trifluoroacetic acid (TFA) (99%); and tri-
methyl orthoformate (99%) were purchased from Acros
Organics. N-Boc-cadaverine (≥97%); 1,4-diaminobutane (99%);
dicyclohexylcarbodiimide (DCC) (99%); N,N-diisopropyl-
ethylamine (DIPEA) (Atofina EDIPA) (99%); 1-hydroxybenzo-
triazole hydrate (HOBt hydrate); methanol (≥99.8%);
propargylamine (98%); propynoic acid (95%); and triethyl
amine (≥99%) were purchased from Sigma Aldrich.
Dichloromethane (DCM) (≥99%) was purchased from Fisher
Chemical. Sodium acetate × 3·H2O for analysis (99.5%);
sodium dihydrogen phosphate (99%) pure; and zinc acetate ×
2·H2O for analysis (99.5%) were purchased from Grüssing.
DMSO ROTIDRY® (≤200 ppm H2O) (≥99.5%); potassium
hydroxide (≥85%) Ph. Eur. pellets; sodium chloride (≥99.5%)
p. a, ACS, ISO; sodium hydroxide (≥99%); and sodium sulfate
(≥99%) were purchased from Roth. Tetrahydrofuran (THF)
(≥99.7%) for HPLC was purchased from VWR. 1,6-
Diaminohexane (≥98%); cystamine hydrochloride (≥97%); and
3-maleimidopropionic acid N-hydroxysuccinimide ester (99%)
were purchased from Alfa Aesar. 4-Hydroxybenzaldehyde
(≥98%) for synthesis and sodium hydrogen phosphate
(≥99.5%) for analysis were purchased from Merck. All these
chemicals were used without further purification. Acetone-D6
Fig. 4 Photocytotoxicity of the porphyrin-hPG conjugate 14b and the
control 12d in cellular assays with human epidermoid carcinoma A-253
and squamous carcinoma CAL-27 cells, irradiated with a white light
source (see Experimental section for details). DT: dark toxicity.
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(99.8%); CDCl3 (99.8%) stab. with silver; D2O (99.95%); CD3OD
(99.8%); and THF-D8 (99.5%) were purchased from Deutero
GmbH. 1,3-Diazidopropane,91 hPG19.5-azide 12a,c,d (syn-
thesized from an hPG with Mw = 19.5 kDa and Mn = 8.4 kDa),
78
hPG116-azide 12b (synthesized from an hPG with Mw = 116 kDa
and Mn = 115 kDa),
78,92,93 mPEG propargyl ether (average MW






porphyrinato]-zinc(II) (15),90 and 5,10,15-tris(3-hydroxyphenyl)-
20-[4-(2,3-dihydroxypropoxy)tetrafluorophenyl]porphyrin (7)57,58
were prepared according to the literature or with slight
modifications.
Thin-layer chromatography (TLC)
TLC analysis was performed on Merck silica gel 60 F254 pre-
coated aluminium sheets with fluorescence indicator F254. In
addition, detection of the intrinsic tetrapyrrole fluorescence
was performed with UV light at 366 nm.
Column chromatography
The preparative purification of mixtures by column chromato-
graphy was conducted on silica gel, pore size 60 Å, 40–63 µm
particle size, high purity containing 0.1% Ca from Fluka or
MN Silica Gel 60 M, 0.04–0.063 mm/230–400 mesh, American
Society for Testing (ASTM) for column chromatography from
Machery-Nagel. The diﬀerent eluents and the brands of the
silica gel used in the synthesis are given in the individual
procedures.
Dialysis
Dialysis (dialysis tubing benzoylated, avg. flat width 32 mm
(1.27 in), Sigma Aldrich) was performed in 1 or 2 L beakers
and the solvents were changed 3 times over a period of 24 h.
The solvents used are given in the individual procedures.
NMR spectroscopy
1H, 13C, and 19F spectra were recorded on Bruker BioSpin™
AC250 (1H NMR: 250 MHz), JEOL™ ECX 400 (1H NMR:
400 MHz, 19F NMR: 376 MHz), JEOL™ ECP 500 (1H NMR:
500 MHz, 13C NMR: 126 MHz, 19F NMR: 471 MHz), and Bruker
BioSpin AVANCE700 (1H NMR: 700 MHz, 13C NMR: 176 MHz)
instruments. CDCl3, acetone-D6, D2O, CD3OD, and THF-D8
were used as deuterated solvents. Chemical shifts δ are given
in ppm relative to tetramethylsilane (TMS) as an internal stan-
dard or relative to the resonance of the solvent (1H NMR:
CDCl3: δ = 7.26 ppm, acetone-D6: δ = 2.05 ppm, D2O: δ =
4.79 ppm, CD3OD: δ = 3.31 ppm + 4.78 ppm, and THF-D8 δ =
3.58 ppm + 1.73 ppm, 13C NMR: CDCl3: δ = 77.16 ppm,
acetone-D6: δ = 29.84 ppm + 206.26 ppm, CD3OD: δ =
49.00 ppm, and THF-D8 δ = 67.57 ppm + 25.37 ppm). All
spectra were recorded at RT. Abbreviations for the signals:
s (singlet), bs (broad singlet), d (doublet), t (triplet),
q (quartet), quin (quintet), h (heptet), m (multiplet), dd
(doublet of doublets), dt (doublet of triplets), and td (triplet of
doublets).
MS spectrometry
Electrospray ionization (ESI) mass spectra were measured on
an Agilent 6210 ESI-TOF from Agilent Technologies.
UV/Vis spectroscopy
The UV/Vis measurements were performed on a Specord S300
spectrometer from Analytik Jena at RT. The solvents are given
in the individual procedures.
In vitro biological studies
Human epidermoid carcinoma A-253 and squamous carci-
noma CAL-27 cells were grown in Dulbecco’s modified eagle
medium (DMEM) from cc-pro GmbH with 10% heat inacti-
vated FCS from cc-pro GmbH, 1% penicillin (10 000 IU) and
streptomycin (10 000 µg mL−1) from cc-pro GmbH. A stock
solution (2 mM) of the PS was prepared at 4 °C in DMSO and
kept in the dark. DMEM (without phenol red) with 10% FCS
was used for further dilution to reach concentration 2 or
10 µM of the PS, respectively. In micro plates 2 × 104 cells per
well were seeded with fresh medium (DMEM without phenol
red) containing 10% FCS with 2 µM or 10 µM of the PS and
incubated for 24 h. After exchange of medium (to remove any
PS not taken up by the cells), the photosensitization was per-
formed at RT with a white light source (Schott KL 200 LCD) at
a dose rate of app. 50 J cm−2. The cell viability of the samples
was measured with a Tecan Infinite 200 microplate reader
from Tecan Group AG, Switzerland, at a wavelength of 490 nm,
assessed using the XTT assays98 and the absorbance. A wave-
length of 630 to 690 nm was used to measure the reference
absorbance (for measuring the non-specific readings).
Recrystallization
Recrystallization of the porphyrinoids was performed by dis-
solving the product in the minimum amount of solvent (e.g.
DCM) and layering it with a 3-fold excess of the anti-solvent
(e.g. methanol/water = 9/1, v/v).
Melting point (m.p.) measurements
The m.p. measurements were performed on a Thermovar m.p.
microscope from Reichert.
General synthesis of the zinc-porphyrins 1d, 2h, 2i, and 5c
In a flask with magnetic stirrer the porphyrin 1c, 2f, 2g, or 5b
was dissolved in methanol or a DCM/methanol mixture. A
point of a spatula of sodium acetate and zinc acetate dihydrate
was added to the stirred solution. The solution was stirred for
0.5 to 18 h at RT. The crude product was diluted with ethyl
acetate or DCM and washed with H2O. Afterwards the organic
layer was dried over Na2SO4 and the solution was evaporated
to dryness. The crude product was purified by column chrom-
atography and/or recrystallization from DCM/n-hexane to
obtain the corresponding zinc-porphyrins 1d, 2h, 2i, and 5c.
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Detailed experimental conditions are given in the ESI.† The
products were analyzed by NMR, MS, and UV/Vis spectroscopy.
General synthesis of the porphyrins 2a, 2b, 2c, 2d, 2e, 2f, and
4 using the nucleophilic aromatic substitution with amines
In a flask with magnetic stirrer porphyrin 1a or 1c was dis-
solved in anhydrous DMSO or DMSO/THF mixture under
argon. To the stirred solution the amine was added. The solu-
tion was stirred at 83 to 100 °C for 0.5 to 4 h. The crude
product was diluted with ethyl acetate or DCM and washed
with H2O and/or saturated NaCl-solution. Afterwards the
organic layer was dried over Na2SO4. The crude product was
evaporated to dryness and the remaining residue was purified
by column chromatography and recrystallization to obtain the
porphyrin products 2a, 2b, 2c, 2d, 2e, 2f and 4. Detailed experi-
mental conditions are given in the ESI.† The products were
analyzed by NMR, MS, and UV/Vis spectroscopy.
5,10,15-Tris(3-benzyloxyphenyl)-20-[4-(prop-2-ynylamino)tetra-
fluorophenyl]porphyrin (2g). In a 10 mL flask with magnetic
stirrer 5,10,15-tris(3-benzyloxyphenyl)-20-pentafluorophenyl-
porphyrin (1b) (156 mg, 152 µmol) was dissolved in 3 mL of
anhydrous THF (Acros) under argon. 3 mL of anhydrous
DMSO (Roth) were added. The THF was evaporated in vacuo as
long as the porphyrin stayed in solution. Propargylamine
(98%, 160 µL, 2.44 mmol) was added and the solution was
stirred at 100 °C for 7 h. The crude product was diluted with
100 mL of DCM and washed twice with 100 mL of H2O.
Afterwards the organic layer was dried over Na2SO4. The crude
product was evaporated to dryness and the remaining residue
was purified by column chromatography (DCM/n-hexane = 3/1,
v/v, Machery-Nagel) and recrystallization from DCM/methanol
to obtain 5,10,15-tris(3-benzyloxyphenyl)-20-[4-(prop-2-ynyl-
amino)tetrafluorophenyl]porphyrin (2g) (125 mg, 118 µmol,
78% yield) as a purple solid.
1H NMR (CDCl3, 700 MHz): δ = 8.94 (d,
3J (H,H) = 4.2 Hz,
2H, 2,18-β), 8.89–8.83 (m, 6H, 3,7,8,12,13,17-β), 7.88 (s, 3H,
Ar), 7.86–7.82 (m, 3H, Ar), 7.67 (t, 3J (H,H) = 7.8 Hz, 3H, Ar),
7.53 (d, 3J (H,H) = 7.6 Hz, 6H, Ar), 7.44–7.39 (m, 9H, Ar),
7.38–7.32 (m, 3H, Ar), 5.27 (s, 6H, OCH2), 4.49–4.43 (m, 3H,
NHCH2 + ArF-NH), 2.50 (s, 1H, CuCH) −2.78 ppm (s, 2H,
pyrrole-NH). 13C NMR (CDCl3, 126 MHz): δ = 157.27, 147.56,
146.17, 143.46, 143.30, 138.70, 137.34, 137.04, 131.66, 128.80,
128.19, 128.15, 127.80, 121.66, 121.34, 120.39, 114.91, 110.70,
102.40, 80.43, 73.03, 70.43, 36.13. 19F NMR (CDCl3, 471 MHz):
δ = −139.78 (dd, 3J (F,F) = 22.0 Hz; 4J (F,F) = 8.3 Hz, 2F, m-ArF),
−158.89–(−159.30) ppm (m, 2F, o-ArF). m.p.: 80 °C. HRMS
(ESI): calc. for C68H48F4N5O3
+ ([M + H]+): 1058.3693 found:
1058.3651. UV/Vis (DCM): λmax (ε [M
−1 cm−1]) = 645 (3000), 589
(6000), 548 (6000), 514 (18 000), 419 nm (338 000).
5,10,15-Tris(3-hydroxyphenyl)-20-[4-(N-4-propyneamidobutyl-
amino)tetrafluorophenyl]porphyrin (5a). In a 10 mL flask with
magnetic stirrer propynoic acid (95%, 3.00 µL, 3.40 mg,
46.1 µmol), HOBt hydrate (7.40 mg, 54.8 µmol), DCC (99%,
17.3 mg, 83.0 µmol) was dissolved in 1 mL THF (VWR). The
solution was stirred for 10 min at RT. To the stirred solution
5,10,15-tris(3-hydroxyphenyl)-20-[4-(4-aminobutylamino)tetra-
fluorophenyl]porphyrin (2b) (40.1 mg, 48.9 µmol) was added.
The solution was stirred at RT for 2 h. The crude product was
diluted with 150 mL of ethyl acetate and washed three times
with 50 mL of H2O. Afterwards the organic layer was dried over
Na2SO4. The crude product was evaporated to dryness and the
remaining residue was purified by column chromatography
(DCM/methanol = 94/6, v/v, Fluka) to obtain 5,10,15-tris(3-
hydroxyphenyl)-20-[4-(N-4-propyneamidobutylamino)tetrafluoro-
phenyl]porphyrin (5a) (13.9 mg, 15.9 µmol, 33% yield) as a
purple solid. The relatively low yield is due to the fact that the
product partly decomposed during workup. Also the final
product exhibited a low stability in solution.
1H NMR (THF-D8, 500 MHz): δ = 8.99–8.84 (m, 11H, β +
5,10,15-meso-3-Ar-OH), 7.90 (s, 1H, NHC(O)), 7.69–7.61 (m, 6H,
5,10,15-meso-2,6-Ar), 7.58–7.51 (m, 3H, 5,10,15-meso-5-Ar),
7.22–7.18 (m, 3H, 5,10,15-meso-4-Ar), 5.81 (s, 1H, ArF-NH), 3.69
(q, 3J (H,H) = 6.6 Hz, 2H, ArF-NHCH2), 3.37 (s, 1H, CuCH), 3.35
(q, 3J (H,H) = 6.7 Hz, 2H, CH2NHC(O)), 1.91–1.84 (m, 2H, ArF-
NHCH2CH2), 1.80–1.74 (m, 2H, CH2CH2NHC(O)), −2.73 ppm
(s, 2H, pyrrole-NH). 13C NMR (THF-D8, 126 MHz): δ = 157.32,
157.28, 152.59, 149.08, 147.15, 144.29, 144.16, 138.93, 137.08,
130.49, 128.35, 128.30, 127.06, 123.05, 122.28, 121.37, 115.81,
103.59, 79.52, 73.01, 67.99, 54.96, 46.25, 39.92, 30.71, 29.36,
27.79, 25.86 ppm. 19F NMR (THF-D8, 376 MHz): δ = −142.72–
(−143.27) (m, 2F, m-ArF), −162.78–(−163.07) ppm (m, 2F,
o-ArF). m.p.: >230 °C. HRMS (ESI): calc. for C51H37F4N6O4
+
([M + H]+): 873.2807; found: 873.2806. UV/Vis (acetone): λmax
(ε [M−1 cm−1]) = 645 (3000), 592 (5000), 546 (6000), 512
(16 000), 416 nm (203 000).
5,10,15-Tris(3-hydroxyphenyl)-20-[2,3,5,6-tetrafluoro-4-(N-(2-
((2-aminoethyl)disulfanyl)ethylpropyneamido))-phenyl]por-
phyrin (5b). In a 10 mL flask with magnetic stirrer DCC (99%,
16.0 mg, 76.7 µmol), propynoic acid (95%, 4.82 µL, 73.9 µmol),
and HOBt hydrate (12.0 mg, 88.8 µmol) were dissolved in 1 mL
of THF (VWR) and stirred for 10 min at RT. 5,10,15-Tris(3-
hydroxyphenyl)-20-[2,3,5,6-tetrafluoro-4-(N-(2-((2-aminoethyl)di-
sulfanyl)ethylamino))phenyl]porphyrin (2a) (69.0 mg, 78.0 µmol)
was added and the solution was stirred for 2 h at RT. The crude
product was dissolved in 100 mL of ethyl acetate and washed
three times with 50 mL of H2O. Afterwards the organic layer was
dried over Na2SO4 and the solution was evaporated to dryness.
The crude product was purified by column chromatography
(DCM/methanol = 85/15, v/v, Machery-Nagel) and recrystalli-
zation from DCM/n-hexane to obtain 5,10,15-tris(3-hydroxy-
phenyl)-20-[2,3,5,6-tetrafluoro-4-(N-(2-((2-aminoethyl)disulfanyl)
ethylpropyneamido))phenyl]porphyrin (5b) (56.0 mg, 59.8 µmol,
77% yield) as a purple solid.
1H NMR (acetone-D6, 700 MHz): δ = 9.13–9.10 (bs, 2H, 2,18-
β), 9.04–9.01 (bs, 2H, 3,17-β), 9.00–8.95 (m, 7H, 7,8,12,13-β +
5,10,15-meso-3-Ar-OH), 8.10–8.07 (bs, 1H, NHC(O)), 7.76 (d,
4J (H,H) = 2.1 Hz, 2H, 5,15-meso-2-Ar), 7.75 (d, 4J (H,H) = 2.1 Hz,
1H, 10-meso-2-Ar), 7.73 (d, 3J (H,H) = 7.7 Hz, 2H, 5,15-meso-6-
Ar), 7.72 (d, 3J (H,H) = 8.7 Hz, 1H, 10-meso-6-Ar), 7.66–7.61 (m,
3H, 5,10,15-meso-5-Ar), 7.33 (dd, 3J (H,H) = 8.5, 4J (H,H) = 2.3
Hz, 3H, 5,10,15-meso-4-Ar), 5.91 (t, 3J (H,H) = 7.1 Hz, 1H,
ArF-NH), 4.04 (q,
3J (H,H) = 6.9 Hz, 2H, ArF-NHCH2), 3.68
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(q, 3J (H,H) = 6.6 Hz, 2H, CH2NHC(O)), 3.53 (s, 1H, CuCH),
3.26 (t, 3J (H,H) = 6.7 Hz, 2H, ArF-NHCH2CH2), 3.02 (t,
3J (H,H)
= 6.8 Hz, 2H, CH2CH2NHC(O)), −2.75 ppm (s, 2H, pyrrole-NH).
13C NMR (acetone-D6, 176 MHz): δ = 156.85, 156.80, 152.91,
148.56, 147.22, 143.94, 143.80, 138.96, 137.50, 132.13, 129.94,
128.66, 128.61, 127.19, 127.14, 122.84, 122.80, 122.34, 121.38,
115.98, 108.24, 103.56, 78.69, 74.46, 45.44, 39.57, 39.43,
37.95 ppm. 19F NMR (acetone-D6, 376 MHz): δ = −143.11 (d,
3J (F,F) = 21.0 Hz, 2F, m-ArF), −161.79 ppm (d, 3J (F,F) = 18.9 Hz,
2F, o-ArF). m.p.: >230 °C. HRMS (ESI): calc. for
C51H37F4N6O4S2
+ ([M + H]+): 937.2254 found: 937.2294. UV/Vis
(ethanol): λmax (ε [M
−1 cm−1]) = 645 (3000), 589 (6000), 547
(7000), 512 (18 000), 416 nm (329 000).
5,10,15-Tris(3-hydroxyphenyl)-20-[4-((2-((2-((3-maleimidyl)
propanamido)ethyl)disulfanyl)ethyl)amino)tetrafluorophenyl]
porphyrin (6a). In a 10 mL flask with magnetic stirrer under
argon 5,10,15-tris(3-hydroxyphenyl)-20-[4-((2-((2-aminoethyl)
disulfanyl)ethyl)amino)tetrafluorophenyl]porphyrin (2a)
(122 mg, 138 µmol) was dissolved in 1.5 mL of anhydrous
DMF. 3-(Maleimido)propionic acid N-hydroxysuccinimide ester
(99%, 47.1 mg, 177 µmol) was added and the solution was
stirred for 1 h at RT. The reaction mixture was diluted with
100 mL ethyl acetate and washed four times with 150 mL H2O.
The organic layer was dried over Na2SO4 and the solvent was
evaporated in vacuo. The crude product was purified by
column chromatography (DCM/methanol = 95/5, v/v, Fluka).
The product was recrystallized from n-hexane to obtain
5,10,15-tris(3-hydroxyphenyl)-20-[4-((2-((2-((3-maleimidyl)propan-
amido)ethyl)disulfanyl)ethyl)amino)tetrafluorophenyl]porphyrin
(6a) (116 mg, 112 µmol, 81% yield).
1H NMR (THF-D8, 500 MHz): δ = 9.02–8.85 (bm, 8H, β),
8.75–8.66 (m, 3H, 5,10,15-meso-3-Ar-OH), 7.72–7.61 (m, 6H,
5,10,15-meso-2,6-Ar), 7.55 (t, 3J (H,H) = 7.8 Hz, 3H, 5,10,15-
meso-5-Ar), 7.53–7.44 (m, 1H, NHC(O)), 7.26–7.14 (m, 3H,
5,10,15-meso-4-Ar), 6.74 (s, 2H, HCvCH), 6.11–6.03 (bs, 1H,
ArF-NH), 3.98 (d,
3J (H,H) = 7.3 Hz, 2H, ArF–NHCH2), 3.83–3.69
(m, 2H, CH2N), 3.53 (t,
3J (H,H) = 6.2 Hz, 2H, CH2NHC(O)),
3.19 (t, 3J (H,H) = 6.8 Hz, 2H, ArF-NHCH2CH2S), 2.90 (t,
3J (H,H)
= 6.7 Hz, 2H, SCH2CH2NHC(O)), 2.50–2.36 (m, 2H, C(O)CH2),
−2.72 ppm (s, 2H, pyrrole-NH). 13C NMR (THF-D8, 126 MHz):
δ = 171.04, 170.21, 157.08, 157.04, 148.77, 146.84, 144.03,
143.89, 138.88, 136.97, 134.86, 131.60, 129.65, 128.11, 128.05,
126.80, 122.81, 122.08, 121.16, 115.58, 108.21, 103.20, 45.44,
39.68, 39.07, 38.45, 34.93, 34.91 ppm. 19F NMR (THF-D8,
471 MHz): δ = −142.56–(−142.86) (m, 2F, m-ArF), −162.24–
(−162.47) ppm (m, 2F, o-ArF). m.p.: 185 °C. HRMS (ESI): calc.
for C55H42F4N7O6S2
+ ([M + H]+): 1036.2569 found: 1036.2588.
UV/Vis (methanol): λmax (ε [M
−1 cm−1]) = 645 (3000), 588
(5000), 546 (6000), 512 (16 000), 415 nm (229 000).
5,10,15-Tris(3-hydroxyphenyl)-20-[4-((((5-maleimidyl)propan-
amido)pentyl)amino)tetrafluorophenyl]porphyrin (6b). In a
10 mL flask with magnetic stirrer under argon 5,10,15-tris(3-
hydroxyphenyl)-20-[4-(5-aminopentylamino)tetrafluorophenyl]
porphyrin (2c) (46.1 mg, 55.2 µmol) was dissolved in 1.5 mL
of anhydrous DMF. 3-(Maleimido)propionic acid
N-hydroxysuccinimide ester (99%, 19.8 mg, 73.6 µmol) was
added and the solution was stirred for 1 h at RT. The reaction
mixture was diluted with 100 mL ethyl acetate and washed
four times with 150 mL H2O. The organic layer was dried over
Na2SO4 and the solvent was evaporated in vacuo. The crude
product was purified by column chromatography (DCM/metha-
nol = 95/5, v/v, Fluka). The product was recrystallized from
n-hexane to obtain 5,10,15-tris(3-hydroxyphenyl)-20-[4-((((5-
maleimidyl)propanamido)pentyl)amino)tetrafluorophenyl]por-
phyrin (6b) (35.3 mg, 35.8 µmol, 65% yield).
1H NMR (THF-D8, 500 MHz): δ = 9.02–8.85 (m, 8H, β), 8.76
(s, 3H, 5,10,15-meso-3-Ar-OH), 7.71–7.62 (m, 6H, 5,10,15-meso-
2,6-Ar), 7.55 (t, 3J (H,H) = 7.8 Hz, 3H, 5,10,15-meso-5-Ar),
7.24–7.19 (m, 3H, 5,10,15-meso-4-Ar), 7.17 (t, 3J (H,H) = 5.0 Hz,
1H, NHC(O)), 6.76 (s, 2H, HCvCH), 5.75 (s, 1H, ArF-NH),
3.79–3.72 (m, 2H, C(O)CH2CH2), 3.66 (q,
3J (H,H) = 6.6 Hz, 2H,
ArF-NHCH2), 3.24 (q,
3J (H,H) = 6.5 Hz, 2H, CH2NHC(O)),
2.45–2.38 (m, 2H, C(O)CH2), 1.87 (quin,
3J (H,H) = 7.4 Hz, 2H,
ArF-NHCH2CH2), 1.65–1.51 (m, 4H, ArF-NHCH2CH2CH2CH2),
−2.72 ppm (s, 2H, pyrrole-NH). 13C NMR (THF-D8, 126 MHz):
δ = 171.28, 169.83, 157.27, 157.23, 149.02, 147.10, 144.32,
144.19, 135.10, 128.36, 128.31, 127.15, 127.12, 123.05, 122.25,
121.35, 115.79, 103.65, 46.56, 39.76, 35.25, 35.16, 31.76, 30.66,
25.86 ppm. 19F NMR (THF-D8, 376 MHz): δ = −142.87–
(−143.22) (m, 2F, m-ArF), −162.24 ppm (d, 3J (F,F) = 14.2 Hz, 2F,
o-ArF). m.p.: >300 °C. HRMS (ESI): calc. for C56H44F4N7O6
+
([M + H]+): 986.3284 found: 986.3329. UV/Vis (methanol): λmax
(ε [M−1 cm−1]) = 645 (3000), 588 (6000), 546 (7000), 513
(19 000), 415 nm (257 000).
5,10,15-Tris(3-hydroxyphenyl)-20-[4-((((6-maleimidyl)propan-
amido)hexyl)amino)tetrafluorophenyl]porphyrin (6c). In a
10 mL flask with magnetic stirrer under argon 5,10,15-tris(3-
hydroxyphenyl)-20-[4-(6-aminohexylamino)tetrafluorophenyl]
porphyrin (2d) (78.6 mg, 92.6 µmol) was dissolved in 1.5 mL
of anhydrous DMF. 3-(Maleimido)propionic acid
N-hydroxysuccinimide ester (99%, 30.2 mg, 112 µmol) was
added and the solution was stirred for 1 h at RT. The reaction
mixture was diluted with 100 mL ethyl acetate and washed
four times with 150 mL H2O. The organic layer was dried
over Na2SO4 and the solvent was evaporated in vacuo. The
crude product was purified by column chromatography
(DCM/methanol = 95/5, v/v, Fluka). The product was recrystal-
lized from n-hexane to obtain 5,10,15-tris(3-hydroxyphenyl)-
20-[4-((((6-maleimidyl)propanamido)hexyl)amino)tetrafluoro-
phenyl]porphyrin (6c) (62.8 mg, 62.8 µmol, 68% yield).
1H NMR (THF-D8, 500 MHz): δ = 9.00–8.88 (m, 8H, β),
8.75–8.88 (m, 3H, 5,10,15-meso-3-Ar-OH), 7.69–7.62 (m, 6H,
5,10,15-meso-2,6-Ar), 7.55 (t, 3J (H,H) = 7.8 Hz, 3H, 5,10,15-
meso-5-Ar), 7.20 (dd, 3J (H,H) = 7.9, 4J (H,H) = 2.3 Hz, 3H,
5,10,15-meso-4-Ar), 7.13 (t, 3J (H,H) = 6.0 Hz, 1H, NHC(O)), 6.75
(s, 2H, HCvCH), 5.77 (t, 3J (H,H) = 6.0 Hz, 1H, ArF-NH),
3.78–3.70 (m, 2H, C(O)CH2CH2), 3.66 (q,
3J (H,H) = 7.3 Hz, 2H,
ArF-NHCH2), 3.20 (q,
3J (H,H) = 6.5 Hz, 2H, CH2NHC(O)),
2.44–2.36 (m, 2H, C(O)CH2), 1.85 (quin,
3J (H,H) = 7.4 Hz,
2H, ArF-NHCH2CH2), 1.61–1.51 (m, 4H, ArF-
NHCH2CH2CH2CH2CH2), 1.51–1.41 (m, 2H, ArF-
NHCH2CH2CH2CH2), −2.71 ppm (s, 2H, pyrrole-NH). 13C NMR
Organic & Biomolecular Chemistry Paper





















































































(THF-D8, 126 MHz): δ = 171.26, 169.74, 157.25, 157.21, 149.15,
147.10, 144.33, 144.19, 135.08, 130.53, 128.37, 128.32, 127.17,
127.14, 123.05, 122.24, 121.34, 115.78, 103.65, 46.46, 39.77,
35.24, 35.14, 32.09, 30.85, 30.70, 27.68, 27.51 ppm. 19F NMR
(THF-D8, 471 MHz): δ = −142.88–(−143.17) (m, 2F, m-ArF),
−163.09 ppm (d, 3J (F,F) = 15.9 Hz, 2F, o-ArF). m.p.: 181 °C.
HRMS (ESI): calc. for C57H46F4N7O6
+ ([M + H]+): 1000.3440
found: 1000.3460. UV/Vis (methanol): λmax (ε [M
−1 cm−1]) =
645 (4000), 588 (7000), 545 (8000), 512 (20 000), 415 nm
(263 000).
(±)-5,10,15-Tris(3-hydroxyphenyl)-20-[4-((2-methoxy-1,3-dioxo-
lan-4-yl)methoxy)tetrafluorophenyl]porphyrin (8a). In a sample
tube with magnetic stirrer 5,10,15-tris(3-hydroxyphenyl)-20-[4-
(2,3-dihydroxypropoxy)tetrafluorophenyl]porphyrin (7) (31.2 mg,
37.8 µmol), 4-hydroxybenzaldehyde (98%, 58.8 mg, 472 µmol),
trimethyl orthoformate (99%, 79 µL, 720 µmol), and
indium(III) trifluoromethane sulfonate (99%, 2.8 mg, 4.9 µmol)
were mixed and stirred neat for 3 h. The reaction mixture was
diluted with 100 mL ethyl acetate and washed three times with
100 mL phosphate buﬀer (100 mM, pH 8). The organic layer
was dried over Na2SO4 and the solvent was evaporated
in vacuo. The crude product was purified by column chromato-
graphy (n-hexane/acetone = 3/2, v/v, Fluka) to obtain
(±)-5,10,15-tris(3-hydroxyphenyl)-20-[4-((2-methoxy-1,3-dioxolan-
4-yl)methoxy)tetrafluorophenyl]porphyrin (8a) (20.1 mg, 23.2
µmol, 61% yield).
1H NMR (acetone-D6, 500 MHz): δ = 9.10 (d,
3J (H,H) = 4.0
Hz, 2H, 2,18-β), 9.03 (d, 3J (H,H) = 4.4 Hz, 2H, 3,17-β), 8.98 (d,
3J (H,H) = 2.2 Hz, 4H, 7,8,12,13-β), 9.00–8.87 (bs, 3H, 5,10,15-
meso-3-Ar-OH), 7.78–7.75 (m, 3H, 5,10,15-meso-2-Ar), 7.75–7.71
(m, 3H, 5,10,15-meso-6-Ar), 7.66–7.61 (m, 3H, 5,10,15-meso-5-
Ar), 7.36–7.32 (m, 3H, 5,10,15-meso-4-Ar), 5.97, 5.92 (s, 1H,
acetal-H), 4.91–4.64 (m, 3H), 4.39–4.33 (m, 1H), 4.17–4.07 (m,
1H), 3.41, 3.36 (s, 3H, CH3), −2.74 ppm (s, 2H, pyrrole-NH).
13C NMR (acetone-D6, 126 MHz): δ = 156.83, 156.77, 148.68,
146.77, 143.87, 143.69, 141.25, 139.36, 132.35, 128.68, 128.62,
127.20, 127.16, 122.83, 122.65, 121.45, 117.44, 1.10, 116.00,
115.83, 102.22, 76.82, 75.84, 75.75, 75.12, 66.14, 65.97, 51.54,
51.15 ppm. 19F NMR (acetone-D6, 471 MHz): δ = −141.47–
(−141.71) (m, 2F, m-ArF), −158.70–(−158.92) ppm (m, 2F,
o-ArF). m.p.: >300 °C. HRMS (ESI): calc. for C49H34F4N4O7
+
([M + H]+): 867.2442 found: 867.2456. UV/Vis (ethanol): λmax
(ε [M−1 cm−1]) = 644 (2000), 588 (6000), 545 (6000), 511
(19 000), 415 nm (383 000).
(±)-5,10,15-Tris(3-hydroxyphenyl)-20-[4-((2-(4-hydroxyphenyl)-
1,3-dioxolan-4-yl)methoxy)tetrafluorophenyl]porphyrin (8b). In
a sample tube with magnetic stirrer 4-hydroxybenzaldehyde
(98%, 80.3 mg, 644 µmol), trimethyl orthoformate (99%,
51 µL, 460 µmol), and indium(III) trifluoromethane sulfonate
(99%, 4.2 mg, 7.4 µmol) were mixed and stirred neat for 3 h.
5,10,15-Tris(3-hydroxyphenyl)-20-[4-(2,3-dihydroxypropoxy)tetra-
fluorophenyl]porphyrin (7) (30.0 mg, 36.4 µmol) was added
and the mixture was stirred for another 2 h. The reaction was
quenched with triethyl amine (99%, 500 µL, 3.55 mmol). The
reaction mixture was diluted with 100 mL ethyl acetate and
washed three times with 100 mL phosphate buﬀer (100 mM,
pH 8). The organic layer was dried over Na2SO4 and the solvent
was evaporated in vacuo. The crude product was purified by
column chromatography (n-hexane/acetone = 3/2, v/v, Fluka) to
obtain (±)-5,10,15-tris(3-hydroxyphenyl)-20-[4-((2-(4-hydroxy-
phenyl)-1,3-dioxolan-4-yl)methoxy)tetrafluorophenyl]porphyrin
(8b) (25.3 mg, 27.2 µmol, 75% yield).
1H NMR (acetone-D6, 500 MHz): δ = 9.11–8.88 (bm, 11H, β +
5,10,15-meso-3-Ar-OH), 8.74–8.47 (bs, 1H, acetal-4-Ar-OH),
7.79–7.71 (m, 6H, 5,10,15-meso-2,6-Ar), 7.637 (t, 3J (H,H) =
7.8 Hz, 2H, 5,15-meso-5-Ar), 7.630 (t, 3J (H,H) = 7.9 Hz, 1H, 10-
meso-5-Ar), 7.49, 7.43 (d, 3J (H,H) = 8.1, 8.7 Hz, 2H, acetal-2,6-
Ar), 7.34 (d, 3J (H,H) = 8.4 Hz, 3H, 5,10,15-meso-4-Ar), 6.91 (d,
3J (H,H) = 8.4 Hz, 2H, acetal-3,5-Ar), 6.05, 5.85 (s, 1H, acetal-H),
4.88–4.72 (m, 3H), 4.53–4.09 (m, 2H), −2.75 ppm (s, 2H,
pyrrole-NH). 13C NMR (acetone-D6, 126 MHz): δ = 159.44,
159.26, 156.86, 156.82, 148.74, 146.82, 143.93, 143.74, 141.29,
139.58, 132.79, 130.05, 129.49, 129.39, 129.14, 128.71, 128.64,
127.28, 127.20, 122.90, 122.85, 122.68, 121.60, 116.04, 115.91,
115.88, 105.72, 104.98, 102.30, 76.37, 76.08, 75.87, 75.77,
67.75, 67.51 ppm. 19F NMR (acetone-D6, 471 MHz): δ =
−141.47–(−141.71) (m, 2F, m-ArF), −158.70–(−158.92) ppm (m,
2F, o-ArF). m.p.: 60 °C. HRMS (ESI): calc. for C54H37F4N4O7
+
([M + H]+): 929.2598 found: 929.2632. UV/Vis (DCM): λmax
(ε [M−1 cm−1]) = 645 (2000), 589 (4000), 548 (4000), 514
(12 000), 418 nm (220 000).
(±)-5,10,15-Tris(3-hydroxyphenyl)-20-[4-((2-(4-(oxiran-2-
ylmethoxy)phenyl)-1,3-dioxolan-4-yl)methoxy)tetrafluorophenyl]
porphyrin (8c). In a sample tube with magnetic stirrer
4-(oxiran-2-ylmethoxy)benzaldehyde (92.4 mg, 519 µmol), tri-
methyl orthoformate (99%, 39 µL, 350 µmol), and indium(III)
trifluoromethane sulfonate (99%, 4.2 mg, 7.4 µmol) were
mixed and stirred neat for 3 h. 5,10,15-Tris(3-hydroxyphenyl)-
20-[4-(2,3-dihydroxypropoxy)tetrafluorophenyl]porphyrin (7)
(32.1 mg, 38.9 µmol) and 2 drops of DCM were added and the
mixture was stirred for another 24 h. The reaction was
quenched with triethyl amine (99%, 100 µL, 710 µmol). The
reaction mixture was diluted with 100 mL ethyl acetate and
washed three times with 100 mL phosphate buﬀer (100 mM,
pH 8). The organic layer was dried over Na2SO4 and the solvent
was evaporated in vacuo. The crude product was purified by
column chromatography (n-hexane/acetone = 1/1, v/v, Fluka)
followed by a second column chromatography (n-hexane/
acetone = 3/2, v/v, Fluka) to obtain (±)-5,10,15-tris(3-hydroxy-
phenyl)-20-[4-((2-(4-(oxiran-2-ylmethoxy)phenyl)-1,3-dioxolan-4-
yl)methoxy)tetrafluorophenyl]porphyrin (8c) (10.4 mg,
10.6 µmol, 27% yield).
1H NMR (acetone-D6, 500 MHz): δ = 9.10–8.89 (bm, 11H, β +
5,10,15-meso-3-Ar-OH), 7.77–7.70 (m, 6H, 5,10,15-meso-2,6-Ar),
7.67–7.61 (m, 3H, 5,10,15-meso-5-Ar), 7.57, 7.52 (d, 3J (H,H) =
8.6, 8.6 Hz, 2H, acetal-2,6-Ar), 7.36–7.31 (m, 3H, 5,10,15-meso-
4-Ar), 7.04, 7.03 (d, 3J (H,H) = 8.7, 8.7 Hz, 2H, acetal-3,5-Ar),
6.07, 5.89 (s, 1H, acetal-H), 4.90–4.73 (m, 3H), 4.54–3.17 (m,
5.5H), 2.75–2.54 (m, 1.5H), −2.76–(−2.80) ppm (m, 2H, pyrrole-
NH). 13C NMR (acetone-D6, 126 MHz): δ = 159.84, 159.69,
156.06, 156.00, 143.09, 142.92, 142.91, 131.71, 131.66, 130.80,
130.25, 128.55, 128.28, 127.91, 127.84, 126.44, 126.38, 122.06,
Paper Organic & Biomolecular Chemistry





















































































122.01, 121.86, 121.85, 120.78, 120.76, 115.23, 114.96, 114.37,
114.33, 104.66, 104.64, 103.86, 75.48, 75.30, 75.16, 75.14,
69.37, 69.35, 69.32, 69.26, 66.93, 66.71, 49.76, 49.65, 43.61,
43.51 ppm. 19F NMR (acetone-D6, 471 MHz): δ = −141.31–
(−142.08) (m, 2F, m-ArF), −158.48–(−159.15) ppm (m, 2F,
m-ArF). m.p.: >300 °C. HRMS (ESI): calc. for C54H41F4N4O8
+
([M + H]+): 985.2861 found: 985.2851. UV/Vis (acetone): λmax
(ε [M−1 cm−1]) = 644 (2000), 588 (5000), 545 (5000), 511
(13 000), 415 nm (243 000).
(±)-5,10,15-Tris(3-hydroxyphenyl)-20-[4-((2-(4-(allyloxy)phenyl)-
1,3-dioxolan-4-yl)methoxy)tetrafluorophenyl]porphyrin (9). In a
10 mL flask with magnetic stirrer 1-(allyloxy)-4-(dimethoxy-
methyl)benzene (33.0 mg, 158 µmol), 5,10,15-tris(3-hydroxy-
phenyl)-20-[4-(2,3-dihydroxypropoxy)tetrafluorophenyl]porphyrin
(7) (80.3 mg, 97.4 µmol), and indium(III) trifluoromethane sul-
fonate (99%, 6.4 mg, 11 µmol) were dissolved in 5 mL of nitro-
methane. After 24 h 1 mL of dry THF (Acros) was added and
the reaction mixture was stirred for another 24 h. 1-(Allyloxy)-4-
(dimethoxymethyl)benzene (275 mg, 1.32 mmol) and indium
(III) trifluoromethane sulfonate (99%, 6.6 mg, 12 µmol) were
added. After 3 d the reaction was completed. The reaction
mixture was diluted with 50 mL methanol/triethyl amine
(99 : 1) and filtered over silica gel. The product was recrystal-
lized from DCM/(methanol/H2O 4 : 1 + NH3 (pH 8)) to obtain
(±)-5,10,15-tris(3-hydroxyphenyl)-20-[4-((2-(4-(allyloxy)phenyl)-
1,3-dioxolan-4-yl)methoxy)tetrafluorophenyl]porphyrin (9)
(52.5 mg, 54.2 µmol, 56% yield).
1H NMR (acetone-D6, 700 MHz): δ = 9.10–8.83 (bm, 11H, β +
5,10,15-meso-3-Ar-OH), 7.80–7.69 (m, 6H, 5,10,15-meso-2,6-Ar),
7.66–7.61 (m, 3H, 5,10,15-meso-5-Ar), 7.55, 7.51 (d, 3J (H,H) =
8.6, 8.5 Hz, 2H, acetal-2,6-Ar), 7.34 (d, 3J (H,H) = 8.4 Hz, 3H,
5,10,15-meso-4-Ar), 7.012, 7.006 (d, 3J (H,H) = 8.5, 8.6 Hz, 2H,
acetal-3,5-Ar), 6.07, 5.88 (s, 1H, acetal-H), 6.11–6.05, 5.97–5.89
(m, 1H, CHvCH2), 5.46–5.38, 5.29–5.21, 5.11–5.05 (m, 2 H,
CHvCH2), 4.90–4.72 (m, 3H), 4.61 (d,
3J (H,H) = 5.2 Hz, 1H,
CH2CHv), 4.55–4.41 (m, 1.5H), 4.30 (d,
3J (H,H) = 6.1 Hz, 1H,
CH2CHv), 4.16–4.06 (m, 0.5H), −2.75–(−2.76) ppm (m,
pyrrole-NH). 13C NMR (acetone-D6, 176 MHz): δ = 160.59,
160.44, 156.85, 156.80, 148.43, 147.06, 143.92, 143.74, 142.95,
141.57, 139.62, 134.64, 134.47, 131.36, 130.79, 129.28, 129.03,
128.71, 128.64, 127.26, 127.20, 122.87, 122.83, 122.69, 122.66,
122.65, 121.60, 121.58, 121.57, 117.45, 117.37, 116.03, 115.29,
115.25, 105.51, 104.73, 102.28, 76.29, 76.12, 76.10, 76.07,
75.95, 69.32, 69.26, 67.74, 67.53, 49.78 ppm. 19F NMR
(acetone-D6, 471 MHz): δ = −141.54–(−141.89) (m, 2F, m-ArF),
−158.58–(−158.87) ppm (m, 2F, m-ArF). m.p.: 140–162 °C.
HRMS (ESI): calc. for C57H41F4N4O7
+ ([M + H]+): 969.2911
found: 969.2915. UV/Vis (acetone): λmax (ε [M
−1 cm−1]) = 644
(6000), 589 (13 000), 511 (41 000), 416 nm (231 000).
{5,10,15-Tris(3-hydroxyphenyl)-20-[4-(((1-(3-hydroxypropyl)-
1H-1,2,3-triazol-4-yl)methyl)amino)tetrafluorophenyl]porphyri-
nato}-zinc(II) (10a). In a 25 mL flask with magnetic stirrer
{5,10,15-tris(3-hydroxyphenyl)-20-[4-(prop-2-yn-1-ylamino)tetra-
fluorophenyl]porphyrinato}-zinc(II) (2h) (43.4 mg, 51.0 µmol)
was dissolved in 1 mL of anhydrous DMSO (Acros) under
argon. To the stirred solution 3-azidopropanol (823 mg,
8.14 mmol), L-ascorbic acid sodium salt (20.4 µL, 0.50 M in
H2O, 10.2 µmol), and copper(II) sulfate pentahydrate (12.8 µL,
0.40 M in H2O, 5.10 µmol) were added. The solution was
stirred for 30 min at RT. The crude product was diluted with
100 mL of ethyl acetate and was washed once with 100 mL of
saturated NaCl solution. The aqueous layer was extracted three
times with 50 mL of ethyl acetate. The combined organic
layers were washed four times with 100 mL of saturated NaCl
solution. Afterwards the organic layer was dried over Na2SO4.
The crude product was evaporated to dryness and the remain-
ing residue was purified by column chromatography (DCM/
methanol = 95/5, v/v, Fluka) and recrystallization from DCM to
obtain {5,10,15-tris(3-hydroxyphenyl)-20-[4-(((1-(3-hydroxy-
propyl)-1H-1,2,3-triazol-4-yl)methyl)amino)tetrafluorophenyl]
porphyrinato}-zinc(II) (10a) (47.7 mg, 45.4 µmol, 89% yield)
as purple-red solid.
1H NMR (THF-D8, 700 MHz): δ = 8.97 (d,
3J (H,H) = 4.5 Hz,
2H, 2,18-β), 8.92 (d, 3J (H,H) = 4.5 Hz, 2H, 7,13-β), 8.90 (d,
3J (H,H) = 4.5 Hz, 2H, 8,12-β), 8.88 (d, 3J (H,H) = 4.5 Hz, 2H,
3,17-β), 8.84 (s, 2H, 5,15-meso-Ar-OH), 8.83 (s, 1H, 10-meso-Ar-
OH), 7.95 (s, 1H, triazole-H), 7.65–7.62 (m, 6H, 5,10,15-meso-
2,6-Ar), 7.508 (t, 3J (H,H) = 8.1 Hz, 2H, 5,15-meso-5-Ar), 7.506 (t,
3J (H,H) = 8.1 Hz, 1H, 10-meso-5-Ar), 7.184 (dt, 3J (H,H) =
8.4 Hz, 4J (H,H) = 1.1 Hz, 2H, 5,15-meso-4-Ar), 7.181 (dt,
3J (H,H) = 8.4 Hz, 4J (H,H) = 1.1 Hz, 1H, 10-meso-4-Ar), 6.15 (t,
3J (H,H) = 6.7 Hz, 1H, ArF-NH), 4.89 (d,
3J (H,H) = 6.8 Hz, 2H,
ArF-NHCH2), 4.55 (t,
3J (H,H) = 7.1 Hz, 2H, triazole-NCH2), 3.98
(t, 3J (H,H) = 5.0 Hz, 1H, CH2OH), 2.14–2.09 ppm (m, 2H,
CH2CH2OH).
13C NMR (THF-D8, 176 MHz): δ = 157.02, 157.00,
151.28, 150.96, 150.78, 148.68, 147.32, 146.52, 145.57, 145.51,
139.01, 137.66, 133.33, 132.46, 132.18, 130.62, 129.57, 127.85,
127.81, 127.14, 127.12, 127.09, 127.06, 127.02, 123.20, 123.17,
123.13, 122.99, 122.84, 121.87, 115.27, 110.29, 103.47, 59.05,
47.73, 42.00, 34.41 ppm. 19F NMR (THF-D8, 376 MHz): δ =
−142.62–(−142.92) (m, 2F, m-ArF), −162.03 ppm (d, 3J (F,F) =
17.6 Hz, 2F, o-ArF). m.p.: >300 °C. HRMS (ESI): calc. for
C50H35F4N8O4Zn
+ ([M + H]+): 951.2009; found: 951.1966.
{5,10,15-Tris(3-hydroxyphenyl)-20-[4-(((1-(3-azidopropyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)tetrafluorophenyl]porphyri-
nato}-zinc(II) (10b). In a 25 mL flask with magnetic stirrer
{5,10,15-tris(3-hydroxyphenyl)-20-[4-(prop-2-yn-1-ylamino)tetra-
fluorophenyl]porphyrinato}-zinc(II) (2h) (103 mg, 121 µmol)
was dissolved in 4 mL of anhydrous DMSO (Acros) under
argon. To the stirred solution 1,3-diazidopropane (1.60 g,
12.7 mmol), L-ascorbic acid sodium salt (≥99%, 75.0 mg,
375 µmol), and copper(II) sulfate pentahydrate (32.0 mg,
128 µmol) were added. The solution was stirred for 30 min at
RT. The crude product was diluted with 100 mL of ethyl
acetate and was washed once with 100 mL of saturated NaCl
solution. The aqueous layer was extracted three times with
50 mL of ethyl acetate. The combined organic layers were
washed four times with 100 mL of saturated NaCl solution.
Afterwards the organic layer was dried over Na2SO4. The crude
product was evaporated to dryness and the remaining residue
was purified by column chromatography (DCM/methanol = 96/
4, v/v → 85/15, v/v, Fluka) to obtain two fractions. Both frac-
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tions were recrystallized from n-pentane to obtain: fraction
1 {5,10,15-tris(3-hydroxyphenyl)-20-[4-(((1-(3-azidopropyl)-1H-
1,2,3-triazol-4-yl)methyl)amino)tetrafluorophenyl]porphyrinato}-
zinc(II) (10b) (43.4 mg, 44.4 µmol, 37% yield) and fraction 2 por-
phyrin-dimer (10c) (44.2 mg, 24.2 µmol, 40% yield) as purple-
red solids.
Porphyrin 10b. 1H NMR (acetone-D6, 700 MHz): δ = 8.98 (d,
3J (H,H) = 4.5 Hz, 2H, 2,18-β), 8.97–8.94 (m, 6H, 3,7,8,12,13,17-
β), 8.75–8.70 (bs, 3H, 5,10,15-meso-3-Ar-OH), 7.90 (s, 1H, tri-
azole-H), 7.74–7.72 (m, 3H, 5,10,15-meso-2-Ar), 7.72–7.69 (m,
3H, 5,10,15-meso-6-Ar), 7.59 (t, 3J (H,H) = 7.8 Hz, 3H, 5,10,15-
meso-5-Ar), 7.29 (dd, 3J (H,H) = 8.4 Hz, 4J (H,H) = 2.4 Hz, 3H,
5,10,15-meso-4-Ar), 5.63 (t, 3J (H,H) = 7.3 Hz, 1H, ArF-NH), 4.39
(t, 3J (H,H) = 6.8 Hz, 2H, triazole-NCH2), 4.32 (d,
3J (H,H) =
7.6 Hz, 2H, ArF-NHCH2), 3.29 (t,
3J (H,H) = 6.6 Hz, 2H, N3CH2),
2.09 ppm (t, 3J (H,H) = 6.7 Hz, 2H, N3CH2CH2).
13C NMR
(acetone-D6, 176 MHz): δ = 156.52, 156.50, 151.16, 151.11,
150.85, 150.68, 148.41, 147.06, 146.24, 145.38, 145.30, 138.98,
137.62, 133.47, 132.69, 132.39, 130.98, 129.18, 128.23, 128.20,
127.29, 123.14, 122.92, 122.77, 121.78, 115.41, 115.34, 110.37,
103.55, 48.95, 47.84, 41.28, 41.20 ppm. 19F NMR (acetone-D6,
471 MHz): δ = −142.70 (d, 3J (F,F) = 21.7 Hz, 2F, m-ArF),
−161.13–(−161.51) ppm (m, 2F, o-ArF). m.p.: >300 °C. HRMS
(ESI): calc. for C50H32F4N11O3Zn
− ([M − H]−): 974.1922; found:
974.2182. UV/Vis (DCM): λmax (ε [M
−1 cm−1]) = 647 (4000), 595
(4000), 553 (19 000), 515 (20 000), 422 nm (20 000).
Porphyrin dimer 10c. 1H NMR (acetone-D6, 700 MHz): δ =
8.97–8.93 (m, 12H, 3,7,8,12,13,17-β), 8.91 (d, 3J (H,H) = 4.4 Hz,
2H, 2,18-β), 8.81–8.74 (m, 6H, 5,10,15-meso-3-Ar-OH), 7.74 (m,
6H, 5,10,15-meso-2-Ar), 7.71–7.66 (m, 6H, 5,10,15-meso-6-Ar),
7.58–7.51 (m, 8H, 5,10,15-meso-5-Ar + triazole-H), 7.29–7.24 (m,
6H, 5,10,15-meso-4-Ar), 5.23–5.15 (bs, 2H, ArF-NH), 3.91–3.82
(bs, 4H, triazole-NCH2), 3.70–3.60 (bs, 4H, ArF-NHCH2),
2.04–1.99 ppm (m, 2H, triazole-NCH2CH2).
13C NMR (acetone-
D6, 176 MHz): δ = 156.52, 156.49, 156.41, 151.17, 151.09,
150.87, 150.69, 148.33, 146.97, 145.71, 145.43, 145.32, 138.82,
137.47, 133.49, 132.67, 132.38, 131.00, 128.85, 128.20, 128.16,
127.30, 123.15, 122.99, 122.92, 122.77, 121.80, 115.40, 110.52,
103.46, 47.42, 40.58 ppm. 19F NMR (acetone-D6, 376 MHz): δ =
−141.69–(−142.99) (m, 4F, m-ArF), −161.08 ppm (d, 3J (F,F) =
16.3 Hz, 4F, o-ArF). m.p.: >300 °C. HRMS (ESI): calc. for
C97H61F8N16O6Zn2
+ ([M + H]+): 1825.3410; found: 1827.3568.
UV/Vis (methanol): λmax (ε [M
−1 cm−1]) = 647 (8000), 594




ophenyl]porphyrinato}-zinc(II) (10d). In a 25 mL flask with mag-
netic stirrer {5,10,15-tris(3-hydroxyphenyl)-20-[4-(((1-(3-
azidopropyl)-1H-1,2,3-triazol-4-yl)methyl)amino)tetrafluoro-
phenyl]porphyrinato}-zinc(II) (10b) (20.8 mg, 21.3 µmol) was
dissolved in 3 mL of anhydrous DMSO (Acros) under argon. To
the stirred solution propargyl-α-D-mannopyranoside (8.60 mg,
39.4 µmol), L-ascorbic acid sodium salt (≥99%, 15.0 mg,
75.0 µmol), and copper(II) sulfate pentahydrate (5.00 mg,
20.0 µmol) were added. The solution was stirred for 1 h at RT.
The crude product was diluted with 100 mL of ethyl acetate
and was washed once with 100 mL of saturated NaCl solution.
The aqueous layer was extracted three times with 50 mL of
ethyl acetate. The combined organic layers were washed four
times with 100 mL of saturated NaCl solution. Afterwards the
organic layer was dried over Na2SO4. The crude product was
evaporated to dryness and the remaining residue was purified
by column chromatography (DCM/methanol = 85/15, v/v,




rinato}-zinc(II) (10d) (24.1 mg, 20.2 µmol, 95% yield) as a
purple-red solid.
1H NMR (CD3OD, 500 MHz): δ = 8.94 (d,
3J (H,H) = 4.7 Hz,
2H, 2,18-β), 8.93–8.87 (m, 4H, 7,8,12,13-β), 8.83 (d, 3J (H,H) =
5.0 Hz, 2H, 3,17-OH), 8.01 (s, 1H, NHCH2-triazole-H), 7.92 (s,
1H, OCH2-triazole-H), 7.71–7.63 (m, 6H, 5,10,15-meso-2,6-Ar),
7.59–7.51 (m, 3H, 5,10,15-meso-5-Ar), 7.26–7.19 (m, 3H,
5,10,15-meso-4-Ar), 4.84–4.79 (m, 2H, ArF-NHCH2), 4.71 (d,
2J (H,H) = 12.4 Hz, 1H, OCH2-triazole), 4.58 (s, 1H, Man-H-1),
4.54 (d, 2J (H,H) = 12.3 Hz, 1H, OCH2-triazole), 4.44 (t,
3J (H,H)
= 6.8 Hz, 2H, ArF-NHCH2-triazole-CH2), 4.40 (t,
3J (H,H) = 6.9
Hz, 2H, OCH2-triazole-CH2), 3.81 (dd,
2J (H,H) = 12.1 Hz, 3J (H,
H) = 3.2 Hz, 1H, Man-H-6b), 3.75 (dd, 3J (H,H) = 3.6 Hz, 3J (H,H)
= 1.9 Hz, 1H, Man-H-2), 3.69 (dd, 2J (H,H) = 11.8 Hz, 3J (H,H) =
5.9 Hz, 1H, Man-H-6a), 3.68–3.61 (m, 1H, Man-H-3), 3.58 (t,
3J (H,H) = 9.4 Hz, 1H, Man-H-4), 3.58–3.46 (m, 1H, Man-H-5),
2.51 ppm (t, 3J (H,H) = 6.9 Hz, 2H, ArF-NHCH2-triazole-
CH2CH2).
13C NMR (CD3OD, 126 MHz): δ = 156.69, 151.69,
151.60, 151.34, 151.17, 147.96, 145.93, 145.48, 133.65, 132.76,
132.47, 130.83, 128.31, 127.77, 125.56, 124.45, 123.27, 122.11,
115.44, 103.65, 100.81, 74.90, 72.47, 71.98, 71.13, 68.61, 62.95,
60.72, 41.71, 31.59, 30.72, 30.49 ppm. 19F NMR (CD3OD,
376 MHz): δ = −143.22 (d, 3J (F,F) = 21.5 Hz, 2F, m-ArF),
−162.12 ppm (d, 3J (F,F) = 20.1 Hz, 2F, o-ArF). m.p.: 225 °C.
HRMS (ESI): calc. for C59H47F4N11O9NaZn
+ ([M + Na]+): 1216,
2678; found: 1216, 2535. UV/Vis (methanol): λmax (ε [M
−1
cm−1]) = 647 (6000), 595 (4000), 555 (4000), 515 (25 000),




phyrinato}-zinc(II) (11). In a 25 mL flask with magnetic stirrer
acetobromo-alpha-D-glucose (98%, 110 mg, 263 µmol) was dis-
solved in 3.4 mL of anhydrous DMSO (Roth). NaN3 (99%,
21.0 mg, 320 µmol) was added and the mixture was stirred for
10 min at RT. {5,10,15-tris(3-benzyloxyphenyl)-20-[4-(prop-
2-ynylamino)tetrafluorophenyl]porphyrinato}-zinc(II) (2i)
(150 mg, 134 µmol), L-ascorbic acid sodium salt (700 µL, 1.43
M in H2O, 1.00 mmol), and copper(II) sulfate pentahydrate
(700 µL, 1.43 M in H2O, 1.00 mmol) were added and the solu-
tion was stirred at RT for 52 h. Portions of the reactants were
added after 16 h (acetobromo-alpha-D-glucose (98%, 110 mg,
263 µmol) and NaN3 (99%, 21.0 mg, 320 µmol) dissolved in
2 mL of anhydrous DMSO (Roth), L-ascorbic acid sodium salt
Paper Organic & Biomolecular Chemistry





















































































(700 µL, 1.43 M in H2O, 1.00 mmol) and copper(II) sulfate
pentahydrate (700 µL, 1.43 M in H2O, 1.00 mmol)), 32 h (aceto-
bromo-alpha-D-glucose (98%, 550 mg, 1.31 mmol) and NaN3
(99%, 105 mg, 1.60 mmol) dissolved in 10 mL of anhydrous
DMSO (Roth), L-ascorbic acid sodium salt (3.30 mL, 1.52 M in
H2O, 5.00 mmol) and copper(II) sulfate pentahydrate (3.30 µL,
1.52 M in H2O, 5.01 mmol)), and 48 h (acetobromo-alpha-D-
glucose (98%, 275 mg, 656 µmol) and NaN3 (99%, 52.5 mg,
800 µmol) dissolved in 5 mL of anhydrous DMSO (Roth),
L-ascorbic acid sodium salt (1.70 mL, 1.47 M in H2O,
2.50 mmol) and copper(II) sulfate pentahydrate (1.70 µL, 1.47
M in H2O, 2.50 mmol)) of stirring. Three drops DIPEA were
added and the reaction mixture was stirred for 1 h. The crude
product was diluted with 100 mL of DCM and washed three
times with 50 mL of H2O. Afterwards the organic layer was
dried over Na2SO4. The crude product was evaporated to
dryness and the remaining residue was purified by column
chromatography (DCM/ethyl acetate = 9/1, v/v, Machery-Nagel)




(34.0 mg, 22.7 µmol, 17% yield) as a pink solid.
1H NMR (CDCl3, 500 MHz): δ = 9.01–8.93 (m, 6H,
3,7,8,12,13,17-β), 8.88 (d, 3J (H,H) = 4.3 Hz, 2H, 2,18-β),
7.89–7.80 (m, 6H, Ar), 7.66–7.58 (m, 3H, Ar), 7.43 (s, 1H, tri-
azole-H), 7.39–7.10 (m, 18H, Ar), 5.55 (d, 3J (H,H) = 9.2 Hz, 1H,
H-1 ose), 5.34–5.27 (m, 1H, H-3 ose), 5.21 (t, 3J (H,H) = 9.4 Hz,
1H, H-4 ose), 5.17–5.01 (m, 9H, CH2 + H-2 ose), 4.19 (dd,
vicinal: 3J (H,H) = 12.7 Hz, geminal: 2J (H,H) = 4.7 Hz, 1H, H-6
ose), 4.06–3.99 (m, 1H, H-5 ose), 3.90–3.83 (m, 1H, H-6 ose),
2.02 (s, 3H, OAc), 1.95 (s, 3H, OAc), 1.92 (s, 3H, OAc), 1.65 ppm
(s, 3H, OAc). 13C NMR (CDCl3, 126 MHz): δ = 170.57, 169.95,
169.40, 168.85, 157.06, 150.55, 150.31, 150.19, 150.03, 144.22,
144.17, 136.92, 136.84, 133.04, 132.41, 132.12, 130.65, 128.57,
128.07, 128.01, 127.94, 127.66, 127.59, 127.55, 127.52, 122.14,
121.47, 121.42, 121.15, 119.98, 114.63, 114.59, 111.10, 85.85,
75.26, 72.33, 70.28, 70.20, 67.67, 61.44, 20.71, 20.63, 20.58,
19.95 ppm. 19F NMR (CDCl3, 471 MHz): δ = −140.23–(−140.53)
(m, 2F, m-ArF), −159.31–(−159.55) ppm (m, 2F, o-ArF). m.p.:
120 °C. HRMS (ESI): calc. for C82H64F4N8O12Zn
+ ([M]+):
1492.3871 found: 1492.3994. UV/Vis (DCM): λmax
(ε [M−1 cm−1]) = 585 (3000), 548 (17 000), 513 (19 000), 420 nm
(260 000).
Porphyrin-hPG19.5-conjugate with 3% porphyrins and 10%
azides 13a. In a 10 mL flask with magnetic stirrer hPG19.5-
azide with 13% azides 12a (68.0 mg, 3.34 µmol, 114 µmol
azido groups) was dissolved in 1 mL of anhydrous DMSO
(Acros). {5,10,15-Tris(3-hydroxyphenyl)-20-[4-(prop-2-yn-1-
ylamino)tetrafluorophenyl]porphyrinato}-zinc(II) (2h) (22.0 mg,
26.0 µmol), L-ascorbic acid sodium salt (26.0 µL, 0.5 M in H2O,
13.0 µmol), and copper(II) sulfate pentahydrate (16.0 µL, 0.40
M in H2O, 6.40 µmol) were added and the solution was stirred
at RT for 2 d. The crude product was purified by dialysis
(acetone/H2O = 9/1, v/v) for 2 d to obtain the purple wax-like
product porphyrin-hPG19.5-conjugate with 3% porphyrins and
10% azides 13a (75.0 mg, 2.89 µmol, 19.0 µmol porphyrin and
80.0 µmol azido groups, 87% yield, 84% conversion).
1H NMR (acetone-D6/D2O = 5/1, v/v, 700 MHz): δ = 9.16–8.28
(bs, β), 7.86–6.53 (m, Ar + triazole-H), 4.05–2.72 ppm (m, hPG-
backbone + porphyrin-CH2).
13C NMR (acetone-D6/D2O = 5/1,
v/v, 176 MHz): δ = 155.71, 150.64, 150.37, 150.13, 144.77,
133.14, 132.25, 131.98, 130.53, 127.92, 126.85, 122.39, 121.30,
114.98, 80.50, 80.24, 78.95, 78.66, 72.94, 71.80, 71.36, 71.15,
71.12, 69.85, 69.55, 63.34, 61.53, 53.83 ppm. UV/Vis (acetone/
H2O = 9/1, v/v): λmax = 598, 557, 424 nm. Mw,NMR = 26.000.
Porphyrin-hPG116-conjugate with 4% porphyrins and 1%
azides 13b. In a 5 mL flask with magnetic stirrer hPG116-azide
with 5% azides 12b (55.0 mg, 466 nmol, 36.5 µmol azido
groups) was dissolved in 1 mL of anhydrous DMSO (Acros).
{5,10,15-Tris(3-hydroxyphenyl)-20-[4-(prop-2-yn-1-ylamino)tetra-
fluorophenyl]porphyrinato}-zinc(II) (2h) (30.2 mg, 35.5 µmol),
L-ascorbic acid sodium salt (252 µL, 26 mM in H2O,
6.55 µmol), and copper(II) sulfate pentahydrate (52.0 µL, 0.14
M in H2O, 7.05 µmol) were added and the solution was stirred
at RT for 3 d. Afterwards the reaction mixture was heated to
40 °C for 3 h. The crude product was purified by dialysis
(acetone/H2O = 4/1, v/v) for 6 d to obtain the purple wax-like
product porphyrin-hPG116-conjugate with 4% porphyrins and
1% azides 13b (58.4 mg, 330 nmol, 22.8 µmol porphyrin and
3.10 µmol azido groups, 71% yield, 91% conversion).
1H NMR (D2O, 700 MHz): δ = 9.77–8.51 (bs, β), 8.51–6.98
(m, Ar + triazole-H), 4.32–2.62 ppm (m, hPG-backbone + por-
phyrin-CH2).
13C NMR (D2O, 176 MHz): δ = 154.80, 149.85,
145.88, 143.88, 136.69, 132.44, 127.70, 122.16, 115.05, 107.93,
79.42, 77.91, 72.12, 70.85, 70.69, 70.41, 69.16, 68.87, 62.60,
60.76 ppm. UV/Vis (H2O): λmax = 597, 557, 423 nm. Mw,NMR =
177.000.
Porphyrin-hPG19.5-conjugate with 0.4% porphyrins and
1.6% azides 13c. In a 10 mL flask with magnetic stirrer
hPG19.5-azide with 2% azides 12c (56.0 mg, 2.85 µmol,
14.0 µmol azido groups) was dissolved in 1 mL of anhydrous
DMSO (Acros). {5,10,15-Tris(3-hydroxyphenyl)-20-[4-(prop-2-yn-
1-ylamino)tetrafluorophenyl]porphyrinato}-zinc(II) (2h)
(5.0 mg, 7.05 µmol), L-ascorbic acid sodium salt (26.0 µL, 0.5
M in H2O, 13.0 µmol), and copper(II) sulfate pentahydrate
(16.0 µL, 0.40 M in H2O, 6.40 µmol) were added and the solu-
tion was stirred at RT for 5 min. The crude product was puri-
fied by dialysis (methanol/H2O = 4/1, v/v) for 2 d to obtain the
purple product porphyrin-hPG19.5-conjugate 0.4% porphyrins
and 1.6% azides 13c. The product was directly converted to
14a in the next reaction without drying.
Porphyrin-mPEG-hPG19.5-conjugate with 0.4% porphyrins,
1.3% mPEG, and 0.3% azides 14a. In a 10 mL flask with mag-
netic stirrer porphyrin-hPG19.5-conjugate 0.4% porphyrins and
1.6% azides 13c was dissolved in 3 mL of H2O. mPEG propar-
gyl ether (average MW = 350) (7.0 mg, 20.0 µmol), L-ascorbic
acid sodium salt (26.0 µL, 0.5 M in H2O, 13.0 µmol), and
copper(II) sulfate pentahydrate (16.0 µL, 0.40 M in H2O,
6.40 µmol) were added and the solution was stirred at RT for
1 d. The crude product was purified by dialysis (H2O) for 2 d to
obtain the purple wax-like product porphyrin-mPEG-hPG19.5-
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conjugate with 0.4% porphyrins, 1.3% mPEG, and 0.3% azides
14a (53.0 mg, 2.38 µmol, 1.05 µmol porphyrin, 3.43 µmol
mPEG, and 791 nmol azido groups, 84% yield over two steps).
1H NMR (D2O, 700 MHz): δ = 9.22–8.63 (m, β), 8.42–7.15 (m,
Ar + triazole-H), 4.32–3.35 (m, hPG-backbone + porphyrin-
CH2 + mPEG-CH3), 1.38 (s, CH2-hPG starter unit), 0.89 ppm
(CH3-hPG starter unit).
13C NMR (D2O, 176 MHz): δ = 79.63,
79.41, 78.14, 77.90, 72.12, 70.97, 70.86, 70.69, 70.40, 69.56,
69.42, 69.16, 68.86, 62.59, 60.73, 58.04 ppm. UV/Vis (H2O):
λmax = 600, 559, 429 nm. Mw,NMR = 22.300.
Porphyrin-mPEG-hPG19.5-conjugate with 3% porphyrins, 3%
mPEG, and 7% azides 14b. In a 10 mL flask with magnetic
stirrer porphyrin-hPG19.5-conjugate 3% porphyrins and 10%
azides 13a (59.0 mg, 2.11 µmol, 18.9 µmol porphyrin and
53 µmol azido groups) was dissolved in 2.2 mL of acetone and
800 µL of H2O. mPEG propargyl ether (average MW = 350)
(22.0 mg, 62.9 µmol), L-ascorbic acid sodium salt (26.0 µL,
0.5 M in H2O, 13.0 µmol), and copper(II) sulfate pentahydrate
(21.0 µL, 0.30 M in H2O, 6.30 µmol) were added and the solu-
tion was stirred at RT for 2 d. The crude product was purified
by dialysis (acetone/H2O = 4/1, v/v) for 2 d to obtain the purple
wax-like product porphyrin-mPEG-hPG19.5-conjugate with 3%
porphyrins, 3% mPEG and 7% azides 14b (62.0 mg, 1.99 µmol,
17.8 µmol porphyrin, 17.8 µmol mPEG and 32.5 µmol azido
groups, 94% yield, 35% conversion).
1H NMR (acetone-D6/D2O = 4/1, v/v, 700 MHz): δ = 9.23–8.44
(m, β), 8.20–6.85 (m, Ar + triazole-H), 4.17–2.50 (m, hPG-back-
bone + porphyrin-CH2 + mPEG-CH3), 1.31 (s, CH2-hPG starter
unit), 0.80 ppm (CH3-hPG starter unit).
13C NMR (acetone-D6/
D2O = 4/1, v/v, 176 MHz): δ = 150.02, 144.62, 94.49, 80.19,
79.98, 78.69, 78.44, 72.69, 71.50, 71.16, 70.91, 70.08, 69.64,
69.35, 63.10, 61.30, 58.39, 53.58, 51.50 ppm. UV/Vis (acetone-
D6/D2O = 4/1, v/v): λmax = 597, 556, 423 nm. Mw,NMR = 31.200.
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